A pro-regenerative cell discovered by researchers at Ohio State and the University of Michigan could open the door to potentially groundbreaking immunotherapeutic treatments for diseases such as ALS and multiple sclerosis.

Genentech presented new data on Enspryng (satralizumab-mwge), which was approved by the U.S. Food and Drug Administration in mid-August 2020 as a subcutaneous treatment for adults with anti-aquaporin-4 antibody positive neuromyelitis optica spectrum.